Engineering T cell response to cancer antigens by choice of focal therapeutic conditions

Qi Shao, Stephen O'Flanagan, Tiffany Lam, Priyatanu Roy, Francisco Pelaez, Brandon J Burbach, Samira M Azarin, Yoji Shimizu, John C Bischof

Research output: Contribution to journalArticle

Abstract

Focal thermal therapy (Heat), cryosurgery (Cryo) and irreversible electroporation (IRE) are increasingly used to treat cancer. However, local recurrence and systemic spread are persistent negative outcomes. Nevertheless, emerging work with immunotherapies (i.e., checkpoint blockade or dendritic cell (DC) vaccination) in concert with focal therapies may improve outcomes. To understand the role of focal therapy in priming the immune system for immunotherapy, an in vitro model of T cell response after exposure to B16 melanoma cell lysates after lethal exposures was designed. Exposure included: Heat (50 °C, 30 min), Cryo (−80 °C, 30 min) and IRE (1250 V/cm, 99 pulses, 50 µs pulses with 1 Hz intervals). After viability assessment (CCK-8 assay), cell lysates were collected and assessed for protein release (BCA assay), protein denaturation (FTIR-spectroscopy), TRP-2 antigen release (western blot), and T cell activation (antigen-specific CD8 T cell proliferation). Results showed IRE released the most protein and antigen (TRP-2), followed by Cryo and Heat. In contrast, Cryo released the most native (not denatured) protein, compared to IRE and Heat. Finally, IRE dramatically outperformed both Cryo and Heat in T cell activation while Cryo modestly outperformed Heat. This study demonstrates that despite all focal therapies ability to destroy cells, the ‘quantity’ (i.e., amount) and ‘quality’ (i.e., molecular state) of tumor protein (including antigen) released can dramatically change the ensuing priming of the immune system. This suggests protein-based metrics whereby focal therapies can be designed to prime the immune system in concert with immunotherapies to eventually achieve improved and durable cancer treatment in vivo.

Original languageEnglish (US)
Pages (from-to)130-138
Number of pages9
JournalInternational Journal of Hyperthermia
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cryosurgery
Electroporation
Hot Temperature
T-Lymphocytes
Antigens
Neoplasms
Immunotherapy
Immune System
Proteins
Therapeutics
CD27 Antigens
Protein Denaturation
Sincalide
Experimental Melanomas
Fourier Transform Infrared Spectroscopy
Dendritic Cells
Spectrum Analysis
Vaccination
Western Blotting
Cell Proliferation

Keywords

  • B16
  • CD8 T cell
  • Focal therapy
  • T cell activation
  • antigen
  • antigen presenting cells
  • cancer
  • dendritic cells
  • immune response
  • melanoma
  • proliferation
  • protein denaturation
  • protein release
  • viability
  • western blot

Cite this

Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. / Shao, Qi; O'Flanagan, Stephen; Lam, Tiffany; Roy, Priyatanu; Pelaez, Francisco; Burbach, Brandon J; Azarin, Samira M; Shimizu, Yoji; Bischof, John C.

In: International Journal of Hyperthermia, Vol. 36, No. 1, 01.01.2019, p. 130-138.

Research output: Contribution to journalArticle

@article{85abc40a56a345d7b9683603b0b3b1a4,
title = "Engineering T cell response to cancer antigens by choice of focal therapeutic conditions",
abstract = "Focal thermal therapy (Heat), cryosurgery (Cryo) and irreversible electroporation (IRE) are increasingly used to treat cancer. However, local recurrence and systemic spread are persistent negative outcomes. Nevertheless, emerging work with immunotherapies (i.e., checkpoint blockade or dendritic cell (DC) vaccination) in concert with focal therapies may improve outcomes. To understand the role of focal therapy in priming the immune system for immunotherapy, an in vitro model of T cell response after exposure to B16 melanoma cell lysates after lethal exposures was designed. Exposure included: Heat (50 °C, 30 min), Cryo (−80 °C, 30 min) and IRE (1250 V/cm, 99 pulses, 50 µs pulses with 1 Hz intervals). After viability assessment (CCK-8 assay), cell lysates were collected and assessed for protein release (BCA assay), protein denaturation (FTIR-spectroscopy), TRP-2 antigen release (western blot), and T cell activation (antigen-specific CD8 T cell proliferation). Results showed IRE released the most protein and antigen (TRP-2), followed by Cryo and Heat. In contrast, Cryo released the most native (not denatured) protein, compared to IRE and Heat. Finally, IRE dramatically outperformed both Cryo and Heat in T cell activation while Cryo modestly outperformed Heat. This study demonstrates that despite all focal therapies ability to destroy cells, the ‘quantity’ (i.e., amount) and ‘quality’ (i.e., molecular state) of tumor protein (including antigen) released can dramatically change the ensuing priming of the immune system. This suggests protein-based metrics whereby focal therapies can be designed to prime the immune system in concert with immunotherapies to eventually achieve improved and durable cancer treatment in vivo.",
keywords = "B16, CD8 T cell, Focal therapy, T cell activation, antigen, antigen presenting cells, cancer, dendritic cells, immune response, melanoma, proliferation, protein denaturation, protein release, viability, western blot",
author = "Qi Shao and Stephen O'Flanagan and Tiffany Lam and Priyatanu Roy and Francisco Pelaez and Burbach, {Brandon J} and Azarin, {Samira M} and Yoji Shimizu and Bischof, {John C}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/02656736.2018.1539253",
language = "English (US)",
volume = "36",
pages = "130--138",
journal = "International Journal of Hyperthermia",
issn = "0265-6736",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Engineering T cell response to cancer antigens by choice of focal therapeutic conditions

AU - Shao, Qi

AU - O'Flanagan, Stephen

AU - Lam, Tiffany

AU - Roy, Priyatanu

AU - Pelaez, Francisco

AU - Burbach, Brandon J

AU - Azarin, Samira M

AU - Shimizu, Yoji

AU - Bischof, John C

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Focal thermal therapy (Heat), cryosurgery (Cryo) and irreversible electroporation (IRE) are increasingly used to treat cancer. However, local recurrence and systemic spread are persistent negative outcomes. Nevertheless, emerging work with immunotherapies (i.e., checkpoint blockade or dendritic cell (DC) vaccination) in concert with focal therapies may improve outcomes. To understand the role of focal therapy in priming the immune system for immunotherapy, an in vitro model of T cell response after exposure to B16 melanoma cell lysates after lethal exposures was designed. Exposure included: Heat (50 °C, 30 min), Cryo (−80 °C, 30 min) and IRE (1250 V/cm, 99 pulses, 50 µs pulses with 1 Hz intervals). After viability assessment (CCK-8 assay), cell lysates were collected and assessed for protein release (BCA assay), protein denaturation (FTIR-spectroscopy), TRP-2 antigen release (western blot), and T cell activation (antigen-specific CD8 T cell proliferation). Results showed IRE released the most protein and antigen (TRP-2), followed by Cryo and Heat. In contrast, Cryo released the most native (not denatured) protein, compared to IRE and Heat. Finally, IRE dramatically outperformed both Cryo and Heat in T cell activation while Cryo modestly outperformed Heat. This study demonstrates that despite all focal therapies ability to destroy cells, the ‘quantity’ (i.e., amount) and ‘quality’ (i.e., molecular state) of tumor protein (including antigen) released can dramatically change the ensuing priming of the immune system. This suggests protein-based metrics whereby focal therapies can be designed to prime the immune system in concert with immunotherapies to eventually achieve improved and durable cancer treatment in vivo.

AB - Focal thermal therapy (Heat), cryosurgery (Cryo) and irreversible electroporation (IRE) are increasingly used to treat cancer. However, local recurrence and systemic spread are persistent negative outcomes. Nevertheless, emerging work with immunotherapies (i.e., checkpoint blockade or dendritic cell (DC) vaccination) in concert with focal therapies may improve outcomes. To understand the role of focal therapy in priming the immune system for immunotherapy, an in vitro model of T cell response after exposure to B16 melanoma cell lysates after lethal exposures was designed. Exposure included: Heat (50 °C, 30 min), Cryo (−80 °C, 30 min) and IRE (1250 V/cm, 99 pulses, 50 µs pulses with 1 Hz intervals). After viability assessment (CCK-8 assay), cell lysates were collected and assessed for protein release (BCA assay), protein denaturation (FTIR-spectroscopy), TRP-2 antigen release (western blot), and T cell activation (antigen-specific CD8 T cell proliferation). Results showed IRE released the most protein and antigen (TRP-2), followed by Cryo and Heat. In contrast, Cryo released the most native (not denatured) protein, compared to IRE and Heat. Finally, IRE dramatically outperformed both Cryo and Heat in T cell activation while Cryo modestly outperformed Heat. This study demonstrates that despite all focal therapies ability to destroy cells, the ‘quantity’ (i.e., amount) and ‘quality’ (i.e., molecular state) of tumor protein (including antigen) released can dramatically change the ensuing priming of the immune system. This suggests protein-based metrics whereby focal therapies can be designed to prime the immune system in concert with immunotherapies to eventually achieve improved and durable cancer treatment in vivo.

KW - B16

KW - CD8 T cell

KW - Focal therapy

KW - T cell activation

KW - antigen

KW - antigen presenting cells

KW - cancer

KW - dendritic cells

KW - immune response

KW - melanoma

KW - proliferation

KW - protein denaturation

KW - protein release

KW - viability

KW - western blot

UR - http://www.scopus.com/inward/record.url?scp=85060697457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060697457&partnerID=8YFLogxK

U2 - 10.1080/02656736.2018.1539253

DO - 10.1080/02656736.2018.1539253

M3 - Article

VL - 36

SP - 130

EP - 138

JO - International Journal of Hyperthermia

JF - International Journal of Hyperthermia

SN - 0265-6736

IS - 1

ER -